What Tussipax Treats: Main Uses and Benefits

The therapeutic role of this medication is primarily used to provide supportive relief for certain categories of non-productive coughing. The medication is indicated for calming dry coughs and irritation coughs. This is applicable within clinical settings that involve acute or disruptive symptom patterns.

The medication helps address symptom clusters that may become intense or disruptive, such as exhausting coughing fits and persistent dry irritation, particularly when these symptoms interfere with rest. The use of Tussipax assists with managing these pronounced symptoms, which contributes to improved day-to-day comfort during symptomatic periods.

“Applied in scenarios where additional management of discomfort is required.”

A key use classification is providing assistance when the dry, irritating cough intensifies at night, leading to disturbed sleep. By offering symptomatic relief in this domain, the medication may assist with maintaining functional stability and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Disruptive Coughs This medication is commonly used across conditions characterized by periods of heightened symptoms to provide supportive relief when symptoms interfere with routine activities, such as sleep and daily tasks.

Regulatory References

1. Notice patient - ANSM

The eligibility for using Tussipax (Codeine/Ethylmorphine) is strictly defined by national and international regulatory bodies, primarily based on age, metabolic profile, and physiological status.

Mandatory Exclusions (Contraindications)

Population Category	Exclusion Rule (Official Labeling)
Pediatric Age	Children under 12 years of age for all indications.
Metabolic Profile	Individuals known as CYP2D6 ultra-rapid metabolizers.
Reproductive Status	Women who are breastfeeding.
Respiratory Status	Patients with significant respiratory depression or acute bronchial asthma.
Post-Surgical Status	Pediatric patients (0–18 years) following tonsillectomy or adenoidectomy for OSAS.

---

Restricted Use and Special Populations

The medicine is generally indicated for Adults. However, use is limited or restricted for other groups:

• Adolescents (12–18 years): Use is not recommended if respiratory function is already compromised (e.g., due to severe lung conditions).
• Elderly Patients: Use requires caution and often necessitates a reduced initial dose as stated in the product information.
• Organ Impairment: Patients with hepatic or renal impairment must use with caution and usually require a dose adjustment due to altered drug clearance.
• Pregnancy: Not recommended for prolonged use, particularly in the third trimester.

Tussipax Interactions with other medicines and products

Official regulatory information emphasizes serious interaction risks, primarily based on pharmacodynamic and pharmacokinetic mechanisms.

Key Interacting Medicinal Product Categories

Interaction Classification	Category/Specific Agents	Mechanism & Implication
Contraindicated	Monoamine Oxidase (MAO) Inhibitors (or use within 14 days)	Risk of serious, unpredictable reactions, including CNS excitation or depression.
Serious: Avoid/Limit Use	CNS Depressants (e.g., alcohol, benzodiazepines, other opioids, sedative-hypnotics)	Pharmacodynamic synergism leading to profound sedation, respiratory depression, coma, and death. Reserve co-prescribing only when alternatives are inadequate.
Serious: Avoid/Caution	Strong CYP2D6 Inhibitors (e.g., quinidine, fluoxetine, paroxetine, amiodarone)	Pharmacokinetic alteration via hepatic enzymes; may result in reduced conversion to the active metabolite, morphine, leading to reduced effectiveness.
Caution: Monitor Closely	Serotonergic Drugs (e.g., SSRIs, SNRIs)	Risk of developing Serotonin Syndrome, requiring close patient observation.
Other Interactions	Anticholinergics, Agents that Delay Gastric Emptying	Increased risk of specific adverse effects, such as paralytic ileus or altered absorption of co-administered oral drugs.

The interaction profile requires strict avoidance of concomitant use with MAO inhibitors and close scrutiny of all combinations with CNS depressants or strong CYP2D6 inhibitors. This structure is defined in official government labeling to clearly mandate either avoidance or close monitoring to manage the primary risks of additive sedation, respiratory depression, and altered drug effectiveness.

Tussipax, a combination product of Codeine and Ethylmorphine, mediates its effects through a pure central pharmacodynamic mechanism. Both components function as agonists at the mu-Opioid Receptor (mu-OR), the critical biological target located on neurons within the brainstem, specifically the medullary cough center.

mu-Opioid Receptor Activation and Neuronal Hyperpolarization

This mechanism outlines the molecular cascade: the binding of the active ingredients initiates a G-protein dependent signal that leads to a reduction in the excitability of target neurons. The physiological consequence is neuronal hyperpolarization, resulting in a decreased probability of action potential generation and reduced propagation velocity of sensory signals.

Central Modulation of the Cough Reflex Arc

The additive action of Codeine and Ethylmorphine results in the modulation of the entire afferent limb of the cough reflex arc at the CNS level. By reducing the release of excitatory neurotransmitters in the medulla, this mechanism significantly elevates the cough threshold. This central depressant effect inherently involves the regulation of reflex signaling and is functionally constrained, as its mechanism does not include action on mucus production or clearance.

The administration of Tussipax is standardized across its available pharmaceutical presentations. The medicine is strictly for the oral route of administration and is offered as a film-coated tablet, a syrup, and an oral solution/drops. A fundamental principle of use is that the therapy is for short-term application, restricted to a duration of only a few days and administered solely during the times the cough occurs.

Administration follows specific dosing intervals to manage the combination of Codeine and Ethylmorphine. For adults and adolescents over 15 years and weighing at least 50 kg, the typical single dose delivers 10 mg of Codeine base and 10 mg of Ethylmorphine chlorhydrate equivalent. Administration must be separated by a minimum interval of six hours, with the total intake limited to a maximum of four doses per 24 hours. The cumulative daily intake for each active component is constrained, not to exceed 60 mg per day.

Specific Administration Requirements

Usage Context	Instruction
Preparation	The oral solution/drops form requires dilution in a liquid such as water, milk, or fruit juice prior to intake.
Dose Adjustments	The starting dose for older adults and patients with hepatic impairment must be reduced by half compared to the standard adult dose.
Dose Management	If the standard dose is ineffective, the dosage must not be increased beyond the established maximums, requiring a re-evaluation of the clinical situation.

The procedural structure thus requires determining the appropriate initial dose, observing form-specific preparation (for drops), and maintaining the specified time intervals and daily dose ceiling throughout the brief course of use.

Research Evidence / Overview of Studies for Tussipax

The research overview for Tussipax (Codeine/Ethylmorphine) is primarily based on studies examining how symptoms change over time in conditions associated with cough. These findings describe patterns observed in the studies and are used by regulatory bodies to contextualize the research that supports the drug's regulatory status.

Evidence for Symptomatic Relief of Acute Dry Cough

The available research examining how symptoms evolve in patients with acute dry cough has mainly focused on short-term symptom patterns in adults with acute dry cough associated with upper respiratory tract infections. The studies, which include Randomized Controlled Trials (RCTs) and Systematic Reviews, were used in research exploring how symptoms change over defined time intervals. The main study outcomes examined were objective measures of cough frequency and patient-reported outcomes describing perceived discomfort and cough severity scores.

Findings across the body of research for Codeine-based antitussives have varied. Regulatory reviews have indicated that when changes were observed in the research, the measured change was sometimes small. Research does not determine whether an individual will respond similarly.

Evidence for Persistent and Chronic Cough

The research exploring the use of the active components in chronic cough is highly limited. The data for persistent or chronic cough is largely derived from older, small-scale clinical trials and observational settings. A major research limitation is the absence of recent, high-quality, placebo-controlled RCTs specifically designed to examine long-term changes or the outcomes across the diverse underlying causes of chronic cough.

Research in Special Populations

Studies included various age groups, which led to specific statements regarding use in younger populations. Regulatory bodies have determined that the evidence for Codeine-containing products is insufficient for characterizing data in children under 12 years of age, and the research base has led to specific regulatory statements regarding the study of adolescents between 12 and 18 years old. Research exploring the drug's activity was conducted on populations of adults (age 16 and older), and the findings primarily describe patterns observed in those specific populations.

Key Studies & References

1. MHRA PUBLIC ASSESSMENT REPORT: Oral liquid cough medicines containing codeine: should not be used in children and young people under 18 years
2. Codeine linctus (codeine oral solutions): Proposal to reclassify to prescription only Public Assessment Report (MHRA, referencing limited efficacy evidence)

Common questions about Tussipax (FAQ)

Q: Is Tussipax used to treat cough only, or does it have other approved uses?

Official product information states that Tussipax is primarily authorized for the symptomatic treatment of coughs. While its active ingredient, codeine, is included in other medicines used for pain relief, the labeled purpose of Tussipax is antitussive.

Q: Can Tussipax affect a person's ability to drive or operate machinery?

Yes, official safety warnings indicate this is possible. Because the medicine may cause drowsiness, dizziness, or lightheadedness, regulatory documents note that it can impair the mental and physical abilities required for potentially hazardous tasks such as driving a car or operating machinery.

Q: Does Tussipax interact with cough or cold products that contain a different active ingredient?

Regulatory documents indicate caution when considering combination with other medicines. Official guidance warns against using Tussipax with any other products that cause drowsiness, as this could lead to additive side effects. Official guidance notes that the labels of other cough or cold products should be reviewed to verify they do not contain codeine.

Q: Is Tussipax generally used for people with a history of sleep apnea?

Official safety warnings indicate restrictions for populations with specific respiratory risk factors. Use is not recommended in children and adolescents (12–18 years) who have a high risk for breathing problems, including obstructive sleep apnea. It is also contraindicated for all children who have undergone specific surgical procedures for this condition.

Q: Is it possible for Tussipax not to work for some people? (Genetic variation concern)

Official warnings note that effectiveness can vary due to genetic factors. If an individual has a deficiency or completely lacks the CYP2D6 liver enzyme, which converts codeine into its active form (morphine), an adequate therapeutic effect may not be obtained.

Q: Why do official sources suggest limiting the duration of use for Tussipax?

Regulatory guidance emphasizes short-term use due to the risk of dependence. Prolonged regular use, except under direct medical supervision, may lead to physical and psychological dependence (addiction), which can result in withdrawal symptoms upon cessation.

Q: What does the term "opioid" mean in relation to Tussipax?

Tussipax is classified as an opioid medicine. This means the active ingredients act on specific opioid receptors in the central nervous system to reduce signals, such as the reflex that causes a cough. Codeine, one of the active ingredients, is a semi-synthetic opioid derivative.

Q: Is Tussipax generally considered appropriate for a cough that has lasted longer than three weeks?

Regulatory guidance states the medicine is authorized only for short-term use, not longer than three days without professional medical supervision. If the cough has lasted or not improved within five days, the individual should seek advice to determine the underlying cause.

Q: How is Tussipax different from basic cough syrup without a prescription ingredient?

Tussipax is a prescription-only medicine, unlike basic cough syrups. This difference is due to its inclusion of the opioid derivative codeine, which acts centrally to suppress cough but carries risks of abuse, dependency, and overdose.

Q: Why is Tussipax sometimes a prescription-only medicine?

Many regulatory bodies have reclassified Tussipax and similar codeine-containing products as prescription-only. This decision was based on concerns over the risks of abuse, dependency, and overdose associated with the opioid content when the medicine is used without professional oversight.

Q: Do the side effects of Tussipax generally get better over time?

Official information indicates that the body can adjust to the medicine over time. Some common side effects, such as feeling sleepy or confusion, should generally wear off within a few days as the body adjusts to the medicine.

Q: What are the signs of an allergic reaction to Tussipax?

Serious signs of an allergic reaction may include rash, hives, itching, or swelling of the face, tongue, lips, eyes, or throat. Difficulties with breathing or swallowing are also noted. If these signs occur, immediate medical assistance is necessary.

Q: Does Tussipax cause dry mouth?

Yes. According to official product labeling and drug information sheets, dry mouth is listed as a possible side effect of codeine-containing medicines.

Q: Does taking Tussipax cause headaches?

Yes, headaches are listed as a possible side effect in the official product information for this medicine.

Q: Are there any known food or supplement interactions with Tussipax?

It is generally not possible to say that herbal remedies and supplements are safe to take with codeine, as they are not tested for interactions in the same way as prescription drugs. Official guidance suggests informing the prescribing healthcare professional about all supplements being taken.

Q: Is it safe to take paracetamol (acetaminophen) or ibuprofen with Tussipax?

Regulatory information indicates that it is generally safe to take Tussipax with paracetamol or ibuprofen. To avoid excessive opioid intake, official labeling indicates that individuals should not take combination products (such as co-codamol) if Tussipax is already being taken.

Q: How long does the effect of one dose of Tussipax typically last?

Regulatory dosing instructions mandate a minimum interval of six hours between doses. This minimum time provides an implied indication of the duration of symptomatic relief expected from the medicine.

Q: What should someone do if they miss a scheduled dose of Tussipax?

Official guidance clarifies that if a dose is missed, regulatory instructions indicate it can be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. Regulatory labeling specifically warns that a double dose should not be taken to make up for a forgotten dose.

Q: What is the difference between tolerance and physical dependence in the context of Tussipax?

Tolerance is a phenomenon where the body gets used to the drug's effects, potentially requiring higher doses to achieve the same therapeutic result. Physical dependence means the body requires the drug to function normally and may lead to unpleasant withdrawal symptoms upon sudden cessation.

Q: Do the ingredients in Tussipax have any documented effect on blood pressure?

Yes, official side-effect listings include the possibility of orthostatic hypotension, which is a drop in blood pressure that occurs when an individual stands up. Changes in blood pressure can also be listed as a symptom of the rare but serious adverse effect known as Serotonin Syndrome.

The storage and disposal of Tussipax (Codeine, Ethylmorphine) must strictly follow official regulatory requirements to ensure product stability and prevent accidental exposure.

Required Storage Conditions

• Temperature: Store the medicine at a temperature below 25°C.
• Protection: The product must be stored protected from light and protected from moisture.
• Child Safety: Due to its opioid content, it is mandatory to keep Tussipax out of the sight and reach of children.
• Expiration: Do not use the medicine after the expiry date printed on the package.

Official Disposal Rules

Disposal of unused or expired Tussipax must be managed according to local regulations. It is strictly mandated not to throw away this medicine in the household trash or flush it down wastewater.